Journal ArticleCirc Heart Fail · October 2024
BACKGROUND: Home-time is an emerging, patient-centered outcome that represents the amount of time a patient spends alive and outside of health care facility settings, comprising of hospitals, skilled nursing facilities, and acute rehabilitation centers. St ...
Full textLink to itemCite
Journal ArticleJAMA Cardiol · July 1, 2024
IMPORTANCE: Kidney health has received increasing focus as part of comprehensive heart failure (HF) treatment efforts. However, the occurrence of clinically relevant kidney outcomes in contemporary populations with HF has not been well studied. OBJECTIVE: ...
Full textOpen AccessLink to itemCite
Journal ArticleJAMA Neurol · February 9, 2024
IMPORTANCE: Intracerebral hemorrhage (ICH) is the deadliest stroke subtype, and mortality rates are especially high in anticoagulation-associated ICH. Recently, specific anticoagulation reversal strategies have been developed, but it is not clear whether t ...
Full textOpen AccessLink to itemCite
Journal ArticleJAMA Netw Open · February 5, 2024
IMPORTANCE: Understanding is needed of racial and ethnic-specific trends in care quality and outcomes associated with the US nationwide quality initiative Target: Stroke (TS) in targeting thrombolysis treatment for acute ischemic stroke. OBJECTIVE: To exam ...
Full textOpen AccessLink to itemCite
ConferenceAm Heart J · November 2023
BACKGROUND: An 11-factor random forest model has been developed among ambulatory heart failure (HF) patients for identifying potential wild-type amyloidogenic TTR cardiomyopathy (wtATTR-CM). The model has not been evaluated in a large sample of patients ho ...
Full textOpen AccessLink to itemCite
Journal ArticleCirc Heart Fail · August 2023
BACKGROUND: Coverage for cardiac rehabilitation (CR) for patients with heart failure with reduced ejection fraction was expanded in 2014, but contemporary referral and participation rates remain unknown. METHODS: Patients hospitalized for heart failure wit ...
Full textOpen AccessLink to itemCite
Journal ArticleCirculation · July 4, 2023
BACKGROUND: Existing data and clinical trials could not determine whether faster intravenous thrombolytic therapy (IVT) translates into better long-term functional outcomes after acute ischemic stroke among those treated with endovascular thrombectomy (EVT ...
Full textOpen AccessLink to itemCite
Journal ArticleJ Card Fail · April 2023
INTRODUCTION: Beta-blockers (BB) and renin-angiotensin system inhibitors (RASi) are foundational for the treatment of heart failure with reduced ejection fraction (HFrEF). However, given the increased risk of side effects in older patients, uncertainty rem ...
Full textOpen AccessLink to itemCite
Journal ArticleCommunications in Statistics Theory and Methods · January 1, 2023
Correlated categorical data often arise from studies involving cluster randomized trials, a cluster sampling scheme, or repeated measurements. The intra-cluster correlation coefficient (ICC) is used to estimate the average correlation within clusters. Ther ...
Full textOpen AccessCite
Journal ArticleJAMA Neurol · August 1, 2022
IMPORTANCE: The effectiveness and safety of intravenous alteplase given before or concurrently with endovascular thrombectomy (EVT) is uncertain. Randomized clinical trials suggest there is little difference in outcomes but with only modest precision and i ...
Full textOpen AccessLink to itemCite
Journal ArticleJ Card Fail · April 2022
BACKGROUND: The sodium-glucose cotransporter-2 (SGLT-2) inhibitors form the latest pillar in the management of heart failure with reduced ejection fraction (HFrEF) and appear to be effective across a range of patient profiles. There is increasing interest ...
Full textOpen AccessLink to itemCite
Journal ArticleNeurology · April 2022
Background and objectivesPrior regional or single-center studies have noted that 4% to 7% of eligible patients with acute ischemic stroke (AIS) decline IV tissue plasminogen activator (tPA). We sought to determine the prevalence of tPA declination ...
Full textOpen AccessCite
Journal ArticleJACC Heart Fail · March 2022
OBJECTIVES: The authors sought to characterize associations between initiation of metformin and sulfonylurea therapy and clinical outcomes among patients with comorbid heart failure (HF) and diabetes (overall and by ejection fraction [EF] phenotype). BACKG ...
Full textOpen AccessLink to itemCite
ConferenceStroke · February 2022
Introduction:
Early administration of intravenous tissue plasminogen activator (IV alteplase) improves functional outcomes in patients with acute ischemic stroke (AIS), yet many patients are not treat ...
Full textCite
ConferenceStroke · February 2022
Introduction:
Many patients arrive beyond the guideline-recommended time window for treatment with IV alteplase. For most of these patients, few treatment options exist. There is a need to understand ...
Full textCite
Journal ArticleCirculation · June 15, 2021
BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic has exposed longstanding racial and ethnic inequities in health risks and outcomes in the United States. We aimed to identify racial and ethnic differences in presentation and outcomes for patien ...
Full textOpen AccessLink to itemCite
Journal ArticleJ Clin Transl Sci · September 4, 2020
INTRODUCTION: Missing data are inevitable in medical research and appropriate handling of missing data is critical for statistical estimation and making inferences. Imputation is often employed in order to maximize the amount of data available for statisti ...
Full textOpen AccessLink to itemCite
Journal ArticleAm Heart J · December 2019
International differences in management/outcomes among patients with type 2 diabetes and heart failure (HF) are not well characterized. We sought to evaluate geographic variation in treatment and outcomes among these patients. METHODS AND RESULTS: Among 14 ...
Full textOpen AccessLink to itemCite
Journal ArticleMed Sci Sports Exerc · July 2018
INTRODUCTION: The prognostic value of peak V˙O2 and V˙E/V˙CO2 slope measured during cardiopulmonary exercise (CPX) testing has been well established in patients with advanced heart failure, but blood pressure response to exercise is less well characterized ...
Full textOpen AccessLink to itemCite
Journal ArticleJ Clin Oncol · May 10, 2016
PURPOSE: Reports have suggested that metastatic site is an important predictor of overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC), but these were based on a limited number of patients. We investigate the impact of ...
Full textOpen AccessLink to itemCite
Journal ArticleJ Clin Oncol · November 1, 2013
PURPOSE: Prostate-specific antigen (PSA) kinetics, and more specifically a ≥ 30% decline in PSA within 3 months after initiation of first-line chemotherapy with docetaxel, are associated with improvement in overall survival (OS) in men with metastatic cast ...
Full textOpen AccessLink to itemCite